Centre Expands Centrally License Approving Authority (CLAA) Framework

Syllabus: GS2/Governance

Context

• The Central Government has amended the Drugs Rules, 1945 to bring Cell or Stem Cell derived products, Gene therapeutic products and Xenografts under the ambit of the Centrally License Approving Authority (CLAA) framework.

About

• Under the Drugs and Cosmetics Act, certain specified categories of critical drugs and biological products are under the joint regulatory supervision of the Central and State regulators. 
  • These include vaccines, large volume parenterals (IV solutions > 100 ml) and r-DNA based medicines. 
  • This set is being expanded with this amendment to cover additional emerging technologies.

• Cell or Stem Cell derived products e.g. such as stem cell-based regenerative treatments, CAR-T cell therapies have seen increasing use in treatment of blood cancers. 
• Gene therapeutic products such as gene replacement and gene editing products have found use in treating genetic disorders and various types of cancers. 
• Xenografts are animal tissue-derived products such as heart valves which can be transplanted into humans. These have use in cardiology and orthopedics.
  • Since these technologies represent highly complex, specialized and rapidly evolving areas of medical science, they need enhanced regulatory scrutiny to ensure patient safety. 
• Significance: The inclusion of these products under the CLAA framework will facilitate a system of joint oversight by the Central and State Licensing Authorities, thereby ensuring uniformity in regulatory standards across the country.

The CLAA Framework in India 

• It is a regulatory mechanism under the Drugs and Cosmetics Rules, 1945, through which the Central Government exercises oversight over the licensing of certain critical categories of drugs. 
• The framework is administered by the Central Drugs Standard Control Organization (CDSCO) under the Ministry of Health and Family Welfare.
• Objective: 
  • To ensure uniform national standards in the manufacture of critical drugs.
  • To strengthen quality control, safety, and regulatory oversight.
  • To prevent variations in licensing practices among different States.
• How the CLAA Framework Works?
  • The manufacturer submits a licence application to the State Licensing Authority (SLA).
  • The SLA inspects the manufacturing facility and examines compliance with Good Manufacturing Practices (GMP).
  • If the application is satisfactory, the SLA forwards its recommendation to the CLAA.
  • The CLAA independently evaluates the proposal and grants or rejects the licence.
• Drugs Covered under the CLAA Framework: The Central Government specifies the categories of drugs requiring CLAA approval. These generally include:
  • Blood and blood products, vaccines, intravenous (IV) fluids/Large Volume Parenterals (LVPs), recombinant DNA (r-DNA) products and other critical biological products notified by the Government.
• Role of CDSCO:
  • It functions as the Central License Approving Authority.
  • Approves licences for specified critical drugs.
  • Regulates imports, new drug approvals, and clinical trials.
  • Coordinates with State Drug Control Organisations to ensure uniform enforcement of the Drugs and Cosmetics Act, 1940.

Source: PIB